BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32727552)

  • 1. Determinants of plasma calretinin in patients with malignant pleural mesothelioma.
    Lehnert M; Weber DG; Taeger D; Raiko I; Kollmeier J; Stephan-Falkenau S; Brüning T; Johnen G;
    BMC Res Notes; 2020 Jul; 13(1):359. PubMed ID: 32727552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calretinin as a blood-based biomarker for mesothelioma.
    Johnen G; Gawrych K; Raiko I; Casjens S; Pesch B; Weber DG; Taeger D; Lehnert M; Kollmeier J; Bauer T; Musk AW; Robinson BWS; Brüning T; Creaney J
    BMC Cancer; 2017 May; 17(1):386. PubMed ID: 28558669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of miR-103a-3p in leukocytes-No diagnostic benefit in combination with the blood-based biomarkers mesothelin and calretinin for malignant pleural mesothelioma diagnosis.
    Jiménez-Ramírez C; Gilbert Weber D; Aguilar-Madrid G; Brik A; Juárez-Pérez CA; Casjens S; Raiko I; Brüning T; Johnen G; Cabello-López A
    PLoS One; 2022; 17(10):e0275936. PubMed ID: 36240245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population.
    Aguilar-Madrid G; Pesch B; Calderón-Aranda ES; Burek K; Jiménez-Ramírez C; Juárez-Pérez CA; Ochoa-Vázquez MD; Torre-Bouscoulet L; Acosta-Saavedra LC; Sada-Ovalle I; García-Figueroa J; Alvarado-Cabrero I; Castillo-González P; Báez-Saldaña AR; Pérez-Padilla JR; Osnaya-Juárez J; Rivera-Rosales RM; García-Bazán EM; Bautista-Aragón YL; Lazcano-Hernandez E; Munguía-Canales DA; Argote-Greene LM; Taeger D; Weber DG; Casjens S; Raiko I; Brüning T; Johnen G
    Int J Med Sci; 2018; 15(9):883-891. PubMed ID: 30008600
    [No Abstract]   [Full Text] [Related]  

  • 5. Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma.
    Jiménez-Ramírez C; Casjens S; Juárez-Pérez CA; Raiko I; Del Razo LM; Taeger D; Calderón-Aranda ES; Rihs HP; Acosta-Saavedra LC; Weber DG; Cabello-López A; Pesch B; Ochoa-Vázquez MD; Burek K; Torre-Bouscoulet L; Pérez-Padilla JR; García-Bazan EM; Brüning T; Johnen G; Aguilar-Madrid G
    Lung; 2019 Oct; 197(5):641-649. PubMed ID: 31267149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients.
    Raiko I; Sander I; Weber DG; Raulf-Heimsoth M; Gillissen A; Kollmeier J; Scherpereel A; Brüning T; Johnen G
    BMC Cancer; 2010 May; 10():242. PubMed ID: 20509881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calretinin-expressing lung adenocarcinoma: Distinct characteristics of advanced stages, smoker-type features, and rare expression of other mesothelial markers are useful to differentiate epithelioid mesothelioma.
    Matsuda M; Ninomiya H; Wakejima R; Inamura K; Okumura S; Mun M; Kitagawa M; Ishikawa Y
    Pathol Res Pract; 2020 Mar; 216(3):152817. PubMed ID: 32008868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study.
    Hoda MA; Dong Y; Rozsas A; Klikovits T; Laszlo V; Ghanim B; Stockhammer P; Ozsvar J; Jakopovic M; Samarzija M; Brcic L; Bendek M; Szirtes I; Reid G; Kirschner MB; Kao SC; Opitz I; Weder W; Frauenfelder T; Nguyen-Kim TD; Aigner C; Klepetko W; van Zandwijk N; Berger W; Dome B; Grusch M; Hegedus B
    Eur J Cancer; 2016 Aug; 63():64-73. PubMed ID: 27288871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma.
    Thapa B; Walkiewicz M; Murone C; Asadi K; Deb S; Barnett S; Knight S; Mitchell P; Liew D; Watkins DN; John T
    Pathology; 2016 Dec; 48(7):660-665. PubMed ID: 27780599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The established and future biomarkers of malignant pleural mesothelioma.
    Panou V; Vyberg M; Weinreich UM; Meristoudis C; Falkmer UG; Røe OD
    Cancer Treat Rev; 2015 Jun; 41(6):486-95. PubMed ID: 25979846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
    Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
    J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. c-Met expression and MET amplification in malignant pleural mesothelioma.
    Bois MC; Mansfield AS; Sukov WR; Jenkins SM; Moser JC; Sattler CA; Smith CY; Molina JR; Peikert T; Roden AC
    Ann Diagn Pathol; 2016 Aug; 23():1-7. PubMed ID: 27402216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.
    Attanoos RL; Galateau-Salle F; Gibbs AR; Muller S; Ghandour F; Dojcinov SD
    Histopathology; 2002 Jul; 41(1):42-9. PubMed ID: 12121236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-asbestos-related malignant pleural mesothelioma.
    Kanbay A; Ozer Simsek Z; Tutar N; Yılmaz I; Buyukoglan H; Canoz O; Demir R
    Intern Med; 2014; 53(17):1977-9. PubMed ID: 25175133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyaluronic acid in the pleural fluid of patients with malignant pleural mesothelioma.
    Fujimoto N; Gemba K; Asano M; Fuchimoto Y; Wada S; Ono K; Ozaki S; Kishimoto T
    Respir Investig; 2013 Jun; 51(2):92-7. PubMed ID: 23790737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.
    Stockhammer P; Ploenes T; Theegarten D; Schuler M; Maier S; Aigner C; Hegedus B
    Lung Cancer; 2020 Jan; 139():124-132. PubMed ID: 31778960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical and pathological profile of the pleural malignant mesothelioma: A retrospective study about 30 cases].
    Mlika M; Lamzirbi O; Limam M; Mejri N; Ben Saad S; Chaouch N; Ben Miled K; Marghli A; Mezni F
    Rev Pneumol Clin; 2018 Dec; 74(6):427-435. PubMed ID: 30293912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
    Pass HI; Levin SM; Harbut MR; Melamed J; Chiriboga L; Donington J; Huflejt M; Carbone M; Chia D; Goodglick L; Goodman GE; Thornquist MD; Liu G; de Perrot M; Tsao MS; Goparaju C
    N Engl J Med; 2012 Oct; 367(15):1417-27. PubMed ID: 23050525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of pleural biopsy for the diagnosis of histologic subtype of malignant pleural mesothelioma: Necropsy-based study of 134 cases.
    Barbieri PG; Consonni D; Schneider M
    Tumori; 2022 Feb; 108(1):26-32. PubMed ID: 33719756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
    Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.